retrospect
chart
review
patient
tertiari
referr
center
compar
characterist
clinic
featur
patient
diagnos
human
rhinoviru
hrv
infect
patient
influenza
pandem
respiratori
season
hospit
admiss
rate
intens
care
unit
icu
admiss
mortal
statist
differ
hrv
group
howev
patient
hrv
group
consid
immunocompromis
dult
diseas
human
rhinoviru
hrv
typic
follow
mild
cours
frequent
viral
infect
associ
exacerb
chronic
obstruct
pulmonari
diseas
immunocompromis
adult
sever
diseas
includ
lower
respiratori
infect
increas
mortal
hrv
caus
symptom
typic
upper
respiratori
virus
patient
present
influenzalik
ill
ili
afebril
upper
respiratori
ill
xtag
respiratori
viral
panel
rvp
luminex
corpor
austin
tx
fdaclear
molecular
assay
detect
hrv
use
respiratori
viru
test
institut
initi
rvp
test
provid
diagnosi
patient
uncharacter
respiratori
viru
sought
evalu
whether
sever
diseas
caus
hrv
similar
pandem
influenza
perform
retrospect
chart
review
patient
posit
rvp
septemb
octob
time
viru
detect
epidem
level
total
specimen
submit
viru
patient
specimen
confirm
georgia
public
health
laboratori
inpati
per
polici
sinc
influenza
sampl
type
impli
strain
patient
consid
immunocompromis
activ
treat
malign
hiv
infect
rheumatolog
condit
immunosuppress
therapi
recipi
solid
organ
hematopoiet
stem
cell
transplant
patient
consid
infect
anoth
site
bacteria
virus
fungi
isol
sourc
clinic
diagnosi
pneumonia
urinari
tract
infect
time
test
univari
analysi
compar
hrv
group
perform
use
mantelhaenszel
chisquar
test
categor
variabl
wilcoxon
rank
sum
test
fisher
exact
test
appropri
continu
variabl
analys
perform
use
sa
version
sa
institut
inc
cari
nc
p
valu
consid
statist
signific
specimen
submit
respiratori
viral
test
patient
test
posit
influenza
viru
hrv
virus
parainfluenza
respiratori
syncyti
viru
b
adenoviru
human
metapneumoviru
total
individu
group
hrv
group
exclud
analysi
incomplet
medic
record
age
less
year
one
adult
coinfect
hrv
viru
includ
group
overal
baselin
characterist
tabl
similar
hrv
group
n
group
n
howev
patient
hrv
group
older
mean
age
versu
p
like
diabet
versu
p
immunocompromis
versu
p
clinic
characterist
compar
two
group
patient
tabl
fever
common
group
versu
p
cough
versu
p
ili
criteria
commonli
met
group
hrv
group
versu
p
differ
antibacteri
therapi
two
group
patient
hrv
howev
significantli
patient
group
start
antivir
therapi
hrv
group
tabl
hrv
p
statist
signific
differ
hospit
admiss
rate
intens
care
unit
icu
admiss
rate
length
stay
mortal
rate
two
group
tabl
two
deceas
individu
group
signific
underli
diseas
chronic
lymphocyt
leukemia
breast
cancer
aid
death
individu
potenti
could
attribut
caus
hrv
infect
adult
typic
experi
mild
symptom
due
hrv
infect
patient
test
posit
hrv
admit
admiss
like
relat
underli
diseas
present
individu
individu
hrv
group
studi
comorbid
condit
clinic
case
seri
done
time
frame
indic
hospit
patient
underli
medic
condit
sinc
almost
onethird
individu
end
posit
hrv
admiss
immunocompromis
like
lower
threshold
admit
individu
present
respiratori
ill
ili
institut
previous
test
hrv
provid
insight
epidemiolog
hrv
patient
popul
better
understand
signific
hrv
diseas
particularli
immunocompromis
patient
although
influenza
gener
thought
sever
hrv
infect
inhospit
mortal
rate
among
patient
admit
icu
studi
patient
similar
hrv
group
also
patient
mortal
hrv
group
due
concurr
ill
directli
attribut
hrv
infect
sever
hrv
infect
outbreak
result
death
elderli
describ
descript
morbid
hrv
infect
elderli
increas
recent
publish
studi
also
show
similar
rate
admiss
icu
patient
infect
viru
respiratori
virus
mortal
lower
patient
fewer
immunocompromis
patient
group
possibl
ill
respiratori
viru
hrv
other
may
also
play
role
especi
immunocompromis
transplant
advent
molecular
platform
approv
detect
hrv
enhanc
understand
epidemiolog
sever
diseas
relat
hrv
especi
immunocompromis
comparison
hrv
viru
studi
serv
demonstr
patient
hrv
may
associ
outcom
sever
typic
consid
howev
remain
determin
whether
hrv
play
import
role
sever
outcom
